FBXO22 and lung carcinoma: Deguelin was identified as a small molecule inhibitor of fbxo22, which can enhance the sensitivity of lung cancer radiotherapy in vitro and in vivo, and has good safety, with rich prospects for clinical transformation (Chen et al., 2024).